A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression

← catalyst calendar

NCT04573192

Sponsored by Philogen S.p.A. (industry) · PHIL.MI — their whole pipeline →.

Phase

Phase 1/2

Status

Unknown status

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

142estimated

Sites

Countries

France, Germany, Italy +1

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2021-02-19

actual

When the study began enrolling

Primary completion

Mar 2025

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Dec 2025

estimated

The whole study's end, after follow-up

First posted

2020-10-05

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2024-04-08

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Glioblastoma

Interventions

Drug: L19TNF — also filed as onfekafusp alfa
Drug: Lomustine

Primary outcomes

what the primary-completion date above is the date OF

For Phase 1: DLT

measured For Cohort 1 to Cohort 3 from Day 1 to Day 42 after the first administration of lomustine and study drug (Cycle 1)

For Phase 2: Overall Survival

measured From beginning of treatment to 12 months

Publications

PMID 37224228 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · PHIL.MI's whole pipeline · Catalyst calendar · Every registered study · What changed